A New Diagnosis of Myasthenia Gravis in Frailty Patient Af-fected by Chronic Obstructive Pulmonary Disease Treated With Steroids

1. Key words Myasthenia Gravis; Corticoste-roid COPD; OSA

2. Abstract In July 2017 we observed, in our Internal Medicine Department, the patient F.A. recently affected by recurrent Chronic Obstructive Pulmonary disease (COPD). Anamnesis’ data have underlined the presence of Permanent Atria Fibrillation (FAP) and severe carotid stenosis, treated with ca-rotid endarterectomises (2012). During the hospitalization period the patient used to frequently 1. Key words Myasthenia Gravis; Corticoste-roid COPD; OSAS ask for a help to the medical staff because of the dyspnoea .The patient referred a high heart frequency, probably due to FAP but the presence of COPD and low saturation percentage gave us the idea of administrate intra vein corticosteroids therapy. The patient informed us an improve-ment of the dyspnoea. After a few days of intra-vein corticosteroid therapy the patient referred to have difficulties on doing simple movements or simple command executions such as signing an informed consent. The patient reported similar symptoms in the past described as simple asthe-nia but he never investigated more. In the following days the symptomatology went ingravescent and the patient reported that he “could not keep lifting his head over the neck”. In the suspected neuromuscular pathology a neurologist was consulted. Our Internal Medicine Department can-not perform specific laboratory analysis (anti-receptor of acetylcholine and specific anti-kinase specific muscle) and specific medical therapy (Pyridostigmine) so the patient was transferred to the Department of Neurology in order to do Diagnostic examinations and appropriate care.

Discussion The presence of co-morbidity makes struggling to evaluate the presence of subclinical diseases. In this case the administrations of corticosteroids for the treatment of COPD allowed unmasking the Myasthenia Gravis present only in the subclinical phase. Conclusion The presence of COPD can determinate an augmented cardiovascular risk in elderly patients. There are, even, some difficulties to evaluate the real presence of important, but subclinical dis-ease, like the Myasthenia Gravis.

3. IntroductionAlthough Evidence Based Medicine is the reference for clinical activity and scientific research, Case Report provides useful in-formation for the advancement of scientific knowledge. The sin-gle Case Report represents the description of scientific evidence that may be undergoing to further investigation to confirm or deny the validity of the same. Numerous scientific publications underline the existence of a correlation between respiratory disease and cardiovascular risk associated to a neuron-vegetative dystopian substrate or an or-tho- and para -sympathetic system imbalance [1-4]. We report our Clinical experience of a case of ventricular fibrillation in a frailty patient with electrolytes disorder (Table. 1) due to gastro enteric disease.

4. Case ReportIn July 2017 we observed, in our Internal Medicine Depart-ment, the patient F.A. recently affected by recurrent Chronic Obstructive Pulmonary disease (COPD). Anamnesis’ data have underlined the presence of Permanent Atria Fibrillation (FAP) and severe carotid stenosis treated with carotid endarterecto-mises (2012). During the visit in the Emergency Room the patient was sub-jected to laboratory tests (Tabe.1). After that the patient has been hospitalized. During the hospitalization period in the Emergency Room the patient has undergone/underwent to the following instrumental examinations: - Rx chest (07/07/2017): ACCENTUAZIONE DELLA TRAMA INTERSTIZIALE PREVALENTE IN SEDE BASALE. signs of COPD. - ECG (07/07/2017): FAP at 87 BPM. - EGA ART (Tab. 1) The patient underwent to the following therapy: - In emergency (07/07/2017): - URBASON 40 mg in saline solution 250 cc IN A DAY; - SALBUTAMOLO 100 mcgr 2 PUFF in a day In the Internal Medicine Department the patient is subjected to laboratory tests (Table.1): During the hospitalization the patient underwent to the follow-ing therapy: - URBASON 40 mg in saline solution 250 cc bis in a day; - ceftriaxone 2 gr (intravein in saline solution) and - klacid 500 1 cp x 2 (oral administration) for high value of WBC in COPD - seretide 50/500 1 puff x 2 and spiriva 1 puff la sera for global bronchodilator therapy - almarythm 1 cp x 2 and xarelto 20 1 cp ore 14 for controlrhythm and anticoagulation in FAP - lasix 25 1 cp per ipertensione arteriosa o2 tp 3 litri minuto for support therapy During the hospitalization period the patient has undergone to the following instrumental examinations that have shown: - Neurological Videat (11/01/2017): At the neurological check-up the patient showed radiating hypoesthesia, localized mostly at the trunk and upper girdle musculature. In particular he referred diplopic of the horizontal gaze, fatigue on maintain-ing the vertical gaze to the top and all the others repeating move-ments of the crania musculature; difficulty on elevating the upper limb and maintaining this position. The upper limb reflexes were weak but after repeated drumming we evoked them. The muscle mass weren’t sore. We recommend to do a chest C.T. with mdc, assay of acetylcholine anti-receptors antibodies, (MuSK) and to do a repeated nervous stimulation. - elettro neurografia sensitive and motor (12/07/2017): figure. 1 - electromyography of the upper limb (12/07/2017): fig-ure. 2 - Echocardiogram (14/07/2017): left ventricle hypertro-phy. Fe 55%. Bi-atrial dilatation, not pericardical effusion. - Chest C.T. with mdc (17/07/2017): fibrotic streak in left baseline site; Hyper plastic lymph nodes by reactive nature against the main lymph nodes hilum-mediastinal stations. During the hospitalization period the patient used to frequently ask for a help to the medical staff because of the dyspnoea. The patient referred a high heart frequency, probably due to FAP but the presence of COPD and low saturation percentage gave us the idea to administrate intra vein corticosteroids therapy. The pa-tient referred an improvement of the dyspnoea. After a few days of intra-vein corticosteroid therapy the patient referred to have difficulties on doing simple movements or simple command ex-ecutions such as signing an informed consent. The patient re-ported similar symptoms in the past described as simple asthenia but he never investigated more. In the following days the symp-tomatology went ingravescent and the patient reported that he “could not keep lifting his head over the neck” [5-9]. In the sus-pected neuro-muscular pathology a neurologist was consulted. Our Internal Medicine Department cannot performed specific laboratory analysis (anti-receptor of acetylcholine and specific anti-kinase specific muscle) therefore an anaesthesiology’s vid-eat have advised us that the patient do not need a rianimatory assistance but was indicated to transfer the patient into a neuro-logical department for specialized follow-up. In the neurologi-cal Department the patient received the specific laboratory tests end the specific medical therapy (Pyridostigmine). Actually the patient is in follow-up for COPD and has a good quality of life with a bronchodilator therapy without steroids (Glicopirronum/ Indacaterol).

5. DiscussionThe presence of co-morbidity makes so difficult to evaluate the presence of subclinical diseases. In this case the administration of corticosteroids for the treatment of COPD has allowed un-masking the Myasthenia Gravis present only in the subclinical phase.

6. ConclusionThe presence of COPD can determinate an augmented cardio-vascular risk in elderly patients. There are, even, some difficul-ties to evaluate the real presence of important, but subclinical disease, like the Myasthenia Gravis.

References 1. Murrey CJ Lopez, and coll. Disability in COPD. Lancet (97): 349; 1198.

2. Papaioannou AI, Bartziosak K, loukides S. Cardiovascular comor-bidities in hospitalized COPD patients: a determinant of future risk ?. Eur Respir J. 2015.

3. Han R, Zou J, Shen X, coll. The risk factors of COPD. Zhonghua Jie He He Hu Xi Zhi. 2015; 38 (2): 93-8.

4. Konecny T, Park JY, Somers KR and coll. Relationship of COPD to atrial and ventricular arrhythmias. Am J. Cardiol. 2014; 114 (2): 272- 277.

5. Rutten FH, Cramer HT, Grobbee DE, and coll. Unrecognized CHF in elderly patients with stable COPD. Eur Heart J. 2005; (18): 1887-94.

6. Rutten FH, Cramer HT, LammersJW, And coll. CHF and COPD. Eur J. Heart Fail. 2005.

7. Matera MG, Rogliani P, Calzetta L, Cazzola M. Safety Consideration with Dual Bronchodilator therapy in COPD: An Update. Drug Saf. 2016; 39(6): 501-8.

8. Men XQ, Wang YK, Li J Wei YQ, Xue C, Wang HQ. Nocturnal heart rhythm disorder in patients with obstructive sleep apnea syndrome. 2000; 93 (46): 3655-8.

9. Parissis JT, Andreoli C, Kadoglov N, and coll. Differences in clini-cal Characteristics, management and short-term outcome among acute heart failure patients with COPD and those without this co-morbidity. Clin. Res Cardiol. 2014; 103 (9): 733-41.

Marchitto N.A New Diagnosis of Myasthenia Gravis in Frailty Patient Af-fected by Chronic Obstructive Pulmonary Disease Treated With Steroids. Annals of Clinical and Medical Case Reports 2023